Skip to main content
. Author manuscript; available in PMC: 2025 Apr 18.
Published in final edited form as: Cell Chem Biol. 2023 Dec 6;31(4):805–819.e9. doi: 10.1016/j.chembiol.2023.11.007

Figure 7: Prenylated isoflavones are active across MYC-driven cancers.

Figure 7:

(A) Cell viability assays from four lung cancer lines treated with pomiferin for 72 h. Data represent mean ± S.D. of three biological replicates.

(B) MYCN abundance measured in SCLC NCI-H69 cells treated with isopomiferin for 24 h.

(C) Western blot analysis of cMYC protein abundance Sy5Y NBL cells treated with pomiferin for 24 h.

(D) Western blot analysis of MYCL protein abundance NCI-H209 SCLC cells treated with isopomiferin for 24 h.

(E) cMYC abundance in NSCLC A549 cells treated with isopomiferin for 24 h.

(F) qPCR measurement of CCL5 transcript in A549 cells following isopomiferin treatment for 48 h.